Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Escitalopram
Drug ID BADD_D00809
Description Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram].[A185420] It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class.[A185726] Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822]
Indications and Usage Escitalopram is indicated for both acute and maintenance treatment of major depressive disorder (MDD) and for the acute treatment of generalized anxiety disorder (GAD).[L8513] It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.[L8516]
Marketing Status approved
ATC Code N06AB10
DrugBank ID DB01175
KEGG ID D07913
MeSH ID D000089983
PubChem ID 146570
TTD Drug ID D08RBC
NDC Product Code 80425-0320; 50090-4915; 51655-284; 53002-1431; 67296-1200; 0456-2010; 0456-2020; 69097-848; 70518-1785; 71335-1030; 0615-8366; 42708-163; 45865-699; 55700-847; 69844-079; 72189-424; 72189-451; 16729-168; 43547-281; 43547-282; 61919-652; 63187-281; 68001-456; 68071-5248; 68788-7461; 69844-077; 70934-630; 68001-454; 68071-2035; 68645-520; 68788-7510; 69844-078; 70934-957; 71205-344; 71610-425; 71610-534; 72189-449; 16571-755; 16729-170; 50090-2196; 51655-236; 53002-2438; 60760-393; 68788-7912; 70518-2317; 70771-1145; 71335-1002; 71335-1187; 71335-1307; 16571-757; 51655-766; 54838-551; 70518-2430; 70771-1147; 50090-4363; 50090-5312; 50090-6534; 51655-116; 51655-149; 69097-847; 69097-849; 70518-1876; 71205-325; 76282-250; 76282-251; 42708-155; 50090-1930; 70518-2472; 70518-3151; 70771-1146; 82982-030; 43547-280; 50090-6190; 51655-277; 55700-818; 63187-217; 67296-1597; 68001-455; 68645-519; 0456-2005; 70518-1805; 70518-2597; 71335-1571; 72189-438; 0615-8365; 72789-194; 76282-249; 16571-756; 33342-053; 60760-170; 65162-705; 71205-782; 71335-1241; 71335-2058; 0615-8348; 16729-169; 43063-661
UNII 4O4S742ANY
Synonyms Escitalopram | Escitalopram Oxalate | Lexapro
Chemical Information
Molecular Formula C20H21FN2O
CAS Registry Number 128196-01-0
SMILES CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Infection parasitic11.01.08.003--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Influenza like illness08.01.03.0100.000144%
Ingrowing nail23.02.05.011--Not Available
Inguinal hernia07.16.02.0010.000019%Not Available
Initial insomnia19.02.01.005; 17.15.03.0050.000051%Not Available
Injection site bruising24.07.06.017; 23.03.11.015; 12.07.03.042; 08.02.03.0420.000074%Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.0010.000106%Not Available
Injection site induration08.02.03.007; 12.07.03.0070.000235%Not Available
Injection site mass12.07.03.010; 08.02.03.0090.000286%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.000383%Not Available
Injection site pruritus12.07.03.014; 23.03.12.007; 08.02.03.0130.000074%Not Available
Injection site reaction12.07.03.015; 08.02.03.0140.000415%
Injection site warmth12.07.03.036; 08.02.03.0360.000074%Not Available
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.0020.001563%
Intentional self-injury19.12.01.002; 12.01.08.0360.000626%Not Available
International normalised ratio increased13.01.02.008--
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Intracranial pressure increased17.07.02.0020.000038%Not Available
Intraventricular haemorrhage17.08.01.017; 24.07.04.0080.000028%Not Available
Iritis10.02.01.022; 06.04.03.002--Not Available
Iron deficiency anaemia14.13.02.001; 01.03.01.0020.000019%Not Available
Irritability19.04.02.013; 08.01.03.0110.000853%
Irritable bowel syndrome07.02.04.003; 19.24.01.003--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.000142%Not Available
Jaundice neonatal09.01.01.008; 01.06.04.006; 18.04.08.0010.000019%Not Available
Joint dislocation15.01.07.002; 12.04.02.007--Not Available
Joint stiffness15.01.02.003--Not Available
Judgement impaired19.05.01.009; 17.03.03.0050.000038%Not Available
The 14th Page    First    Pre   14 15 16 17 18    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene